Correction: Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future

Código QR

Correction: Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future

Guardado en:

Detalles Bibliográficos
Formato:	article
Lenguaje:	EN
Publicado:	BMJ Publishing Group 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/7dc9ac60a1c343588f4963c6e53c9806
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future
por: Razan Alzeibak, et al.
Publicado: (2021)

Correction: In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis
Publicado: (2021)

In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis
por: In-San Kim, et al.
Publicado: (2021)

MET targeted therapy for lung cancer: clinical development and future directions
por: Feng Y, et al.
Publicado: (2012)

Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy.
por: Vincenzo Mazzaferro, et al.
Publicado: (2021)

Production of Long-Acting CNGRC–CPG2 Fusion Proteins: New Derivatives to Overcome Drug Immunogenicity of Ligand-Directed Enzyme Prodrug Therapy for Targeted Cancer Treatment
por: Layla Al-mansoori, et al.
Publicado: (2021)

Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy: a prospective observational study
por: Helen Y Chu, et al.
Publicado: (2021)

Correction notice to “Combination therapy with dendritic cell vaccine and programmed death ligand 1 immune checkpoint inhibitor for hepatocellular carcinoma in an orthotopic mouse model”
por: Chiao-Fang Teng, et al.
Publicado: (2021)

Correction to: ciRS-7 is a prognostic biomarker and potential gene therapy target for renal cell carcinoma
por: Weipu Mao, et al.
Publicado: (2021)

Current Strategies for Tumor Photodynamic Therapy Combined With Immunotherapy
por: Jianfeng Hua, et al.
Publicado: (2021)

Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma
por: Dana S. Neel, et al.
Publicado: (2017)

Non-small cell lung cancer: the era of targeted therapy
por: Antonoff MB, et al.
Publicado: (2012)

Molecular targeted therapy for advanced or metastatic soft tissue sarcoma
por: Jin Yuan MD, et al.
Publicado: (2021)

Combination therapy with dendritic cell vaccine and programmed death ligand 1 immune checkpoint inhibitor for hepatocellular carcinoma in an orthotopic mouse model
por: Chiao-Fang Teng, et al.
Publicado: (2020)

CD8+ TILs in NSCLC differentiate into TEMRA via a bifurcated trajectory: deciphering immunogenicity of tumor antigens
por: Sung-Woo Lee, et al.
Publicado: (2021)

Correction: Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies
Publicado: (2021)

FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036
por: Steven P. Angus, et al.
Publicado: (2021)

A computational method for prioritizing targeted therapies in precision oncology: performance analysis in the SHIVA01 trial
por: Istvan Petak, et al.
Publicado: (2021)

OncoTargets and Therapy
Publicado: (2009)

Correction to: Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer
por: Chunfeng Xie, et al.
Publicado: (2021)

Correction: IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy
Publicado: (2021)

Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy
por: Pascale Lejeune, et al.
Publicado: (2021)

Correction to: Targeting tumor hypoxia and mitochondrial metabolism with anti-parasitic drugs to improve radiation response in high-grade gliomas
por: Faiqa Mudassar, et al.
Publicado: (2021)

Correction: Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting
Publicado: (2021)

Correction: THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy
Publicado: (2021)

Breast reconstruction: current and future options
por: Paul Jr H, et al.
Publicado: (2011)

Correction: Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer
Publicado: (2021)

Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo
por: Jason J. Zoeller, et al.
Publicado: (2017)

Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy
por: Federica Cappuccini, et al.
Publicado: (2021)

Precision oncology- the future of personalized cancer medicine?
por: Ann M. Bode, et al.
Publicado: (2017)

Precision medicine: the foundation of future cancer therapeutics
por: Seung Ho Shin, et al.
Publicado: (2017)

Correction to: MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma
por: Guangbing Xiong, et al.
Publicado: (2021)

Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival
por: Vladimir Lazar, et al.
Publicado: (2021)

Combined 2-deoxy glucose and metformin improves therapeutic efficacy of sodium-iodide symporter-mediated targeted radioiodine therapy in breast cancer cells
por: Chatterjee S, et al.
Publicado: (2015)

Correction to: Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study
por: Shebli Atrash, et al.
Publicado: (2021)

Challenges in the development of future treatments for breast cancer stem cells
por: Shyam A Patel, et al.
Publicado: (2010)

Circulating tumor cells: quintessential precision oncology presenting challenges for biology
por: Rebecca J. Morris
Publicado: (2017)

Live-single-cell phenotypic cancer biomarkers-future role in precision oncology?
por: Grannum R. Sant, et al.
Publicado: (2017)

Crizotinib and ceritinib trigger immunogenic cell death via on-target effects
por: Adriana Petrazzuolo, et al.
Publicado: (2021)

Targeting the duality of cancer
por: Jack L. Arbiser, et al.
Publicado: (2017)